AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$OSCR

Liang Janet sold $326K of OSCR

Liang Janet (President, Oscar Insurance) sold 10,360 shares of Oscar Health, Inc. (OSCR) at $31.45 ($0.33M total) on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Liang Janet
Published Sep 8, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

Provides fresh data on executive holdings, useful for short‑term traders monitoring insider activity.

02

Market read

Small insider sale may cause slight price movement; relevance limited to short‑term traders.

03

What to watch

Pre‑arranged 10b5‑1 plan reduces speculation about motive.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

President Janet Liang sold 10,360 shares for $325,822 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to holdings, but the insider is a top executive, which can influence perception.

Market effects

Sector

Minimal impact on health‑tech sector; similar insider sales have limited ripple.

Regional

No broader regional effect.

Global

Not globally relevant.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • company
    Oscar Health, Inc.

    US‑listed health‑tech insurer.

  • person
    Janet Liang

    President of Oscar Insurance.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OSCR insider trading history →

Related articles

OCT 12
$OSCRMed

OSCR Maintained by UBS -- Price Target Raised to $36

UBS maintained a 'Neutral' rating for Oscar Health (OSCR) but raised its price target to $36 from $26. GuruFocus values OSCR at $24.66, suggesting it is 37.9% overvalued at $34.01. The company has a GF Score of 81/100, with strong growth and momentum but concerns over valuation and profitability. Insiders have sold $26.76M in shares over the past three months.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

tipranks.com2 min